{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:50:32Z","timestamp":1790383832622,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jgar.2023.11.015","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T03:05:09Z","timestamp":1704855909000},"page":"200-209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Dalbavancin real-life utilization among diabetic patients suffering from infections in Italy and Spain: The DALBADIA retrospective cohort study"],"prefix":"10.1016","volume":"36","author":[{"given":"Laura","family":"Morata Ruiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Ruggieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Pasquau Lia\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8571-2124","authenticated-orcid":false,"given":"Miguel","family":"Salavert Llet\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonor","family":"Moreno N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1992-1796","authenticated-orcid":false,"given":"Antonio","family":"Cascio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Tascini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8194-1571","authenticated-orcid":false,"given":"Maria","family":"Loeches Yag\u00fce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Giuseppe","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Comandini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnese","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Antonio","family":"Grossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2023.11.015_bib0001","unstructured":"IDF Diabetes Atlas. Available at: https:\/\/diabetesatlas.org\/#:\u223c:text=Diabetes%20around%20the%20world%20in%202021%3A,%2D%20and%20middle%2Dincome%20countries. Accessed February 6, 2023."},{"key":"10.1016\/j.jgar.2023.11.015_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MRM.0000000000000155","article-title":"The diabetes pandemic and associated infections: suggestions for clinical microbiology","volume":"30","author":"Toniolo","year":"2019","journal-title":"Rev Med Microbiol"},{"key":"10.1016\/j.jgar.2023.11.015_bib0003","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00592-019-01301-0","article-title":"The prevalence of methicillin-resistant Staphylococcus aureus among diabetic patients: a meta-analysis","volume":"56","author":"Stacey","year":"2019","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.jgar.2023.11.015_bib0004","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2337\/dc17-2131","article-title":"Risk of infection in type 1 and type 2 diabetes compared with the general population: a matched cohort study","volume":"41","author":"Carey","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jgar.2023.11.015_bib0005","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00203-020-01818-x","article-title":"Diabetes-associated infections: development of antimicrobial resistance and possible treatment strategies","volume":"202","author":"Akash","year":"2020","journal-title":"Arch Microbiol"},{"key":"10.1016\/j.jgar.2023.11.015_bib0006","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3390\/jcm8111935","article-title":"Bacterial diversity of diabetic foot ulcers: current status and future perspectives","volume":"8","author":"Sadeghpour Heravi","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.jgar.2023.11.015_bib0007","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz505","article-title":"Prognostic utility of the new definition of difficult-to-treat resistance among patients with Gram-negative bloodstream infections","volume":"6","author":"Giannella","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2023.11.015_bib0008","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s15010-014-0678-1","article-title":"Risk factors for enterococcal infection and colonization by vancomycin-resistant enterococci in critically ill patients","volume":"42","author":"Papadimitriou-Olivgeris","year":"2014","journal-title":"Infection"},{"key":"10.1016\/j.jgar.2023.11.015_bib0009","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa161","article-title":"The impact of multidrug-resistant organisms on outcomes in patients with diabetic foot infections","volume":"7","author":"Henig","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2023.11.015_bib0010","series-title":"Diabetes in America","article-title":"Infections associated with diabetes","author":"Egede","year":"2018"},{"key":"10.1016\/j.jgar.2023.11.015_bib0011","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/cpt.726","article-title":"The nephrotoxicity of vancomycin","volume":"102","author":"Filippone","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jgar.2023.11.015_bib0012","series-title":"Diabetic nephropathy","author":"Varghese","year":"2020"},{"key":"10.1016\/j.jgar.2023.11.015_bib0013","first-page":"670","article-title":"Diabetic foot management: multidisciplinary approach for advanced lesion rescue","volume":"59","author":"Brocco","year":"2018","journal-title":"J Cardiovasc Surg (Torino)"},{"key":"10.1016\/j.jgar.2023.11.015_bib0014","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.cmi.2018.07.028","article-title":"Antimicrobial consumption and impact of antimicrobial stewardship programmes in longterm care facilities","volume":"25","author":"Falcone","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2023.11.015_bib0015","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.2147\/IDR.S318322","article-title":"Emerging treatment options for acute bacterial skin and skin structure infections and bloodstream infections caused by Staphylococcus aureus: a comprehensive review of the evidence","volume":"15","author":"Giacobbe","year":"2022","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jgar.2023.11.015_bib0016","first-page":"269","article-title":"Vancomycin resistance in Staphylococcus aureus","volume":"90","author":"McGuinness","year":"2017","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.jgar.2023.11.015_bib0017","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/TCRM.S46","article-title":"Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review","volume":"4","author":"Bennett","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jgar.2023.11.015_bib0018","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/14787210.2020.1746643","article-title":"The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs)","volume":"18","author":"Soriano","year":"2020","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jgar.2023.11.015_bib0019","unstructured":"Xydalba. Summary of product characteristics. Last update December 2022. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xydalba. Accessed 6 February 2023."},{"key":"10.1016\/j.jgar.2023.11.015_bib0020","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ijid.2019.02.013","article-title":"Multicenter clinical experience of real life dalbavancin use in gram-positive infections","volume":"81","author":"Wunsch","year":"2019","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jgar.2023.11.015_bib0021","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2023.11.015_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106503","article-title":"Update on activity of dalbavancin and comparators against clinical isolates of Gram-positive pathogens from Europe and Russia (2017-2018), and on clonal distribution of MRSA","volume":"59","author":"Riccobono","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2023.11.015_bib0023","doi-asserted-by":"crossref","first-page":"ofy331","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety","volume":"6","author":"Rappo","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2023.11.015_bib0024","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1080\/14787210.2020.1798227","article-title":"Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study)","volume":"14","author":"Bai","year":"2020","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jgar.2023.11.015_bib0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13019-017-0690-5","article-title":"Dalbavancin treatment in a deep sternal wound MRSA infection after coronary artery bypass surgery: a case report","volume":"13","author":"Guzek","year":"2018","journal-title":"J Cardiothorac Surg"},{"key":"10.1016\/j.jgar.2023.11.015_bib0026","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diagmicrobio.2018.10.007","article-title":"Dalbavancin for the management of gram-positive osteomyelitis: effectiveness and potential utility","volume":"93","author":"Almangour","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2023.11.015_bib0027","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40121-019-0247-0","article-title":"Dalbavancin use in vulnerable patients receiving outpatient parenteral antibiotic therapy for invasive Gram-positive infections","volume":"8","author":"Bork","year":"2019","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jgar.2023.11.015_bib0028","first-page":"532","article-title":"Dalbavancin for treating prosthetic joint infections caused by Gram-positive bacteria: a proposal for a low dose strategy: a retrospective cohort study","volume":"32","author":"Buz\u00f3n Mart\u00edn","year":"2019","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.jgar.2023.11.015_bib0029","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12941-019-0329-6","article-title":"DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and\/or bloodstream infection produced by Gram-positive cocci","volume":"18","author":"Hidalgo-Tenorio","year":"2019","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.jgar.2023.11.015_bib0030","doi-asserted-by":"crossref","first-page":"e02280","DOI":"10.1128\/AAC.02280-18","article-title":"Safety and efficacy of prolonged use of dalbavancin in bone and joint infections","volume":"63","author":"Morata","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2023.11.015_bib0031","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","article-title":"DALBUSE Study Group (Dalbavancina: Estudio de su uso clinico en Espa\u00f1a). Dalbavancin in the treatment of different Gram-positive infections: a real-life experience","volume":"51","author":"Bouza","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2023.11.015_bib0032","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.2147\/DDDT.S313756","article-title":"Real-world use of dalbavancin in the era of empowerment of outpatient antimicrobial treatment: a careful appraisal beyond approved indications focusing on unmet clinical needs","volume":"15","author":"Gatti","year":"2021","journal-title":"Drug Des Devel Ther"},{"issue":"Suppl","key":"10.1016\/j.jgar.2023.11.015_bib0033","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1093\/ofid\/ofx163.068","article-title":"Efficacy and safety of dalbavancin for the treatment of acute bacterial skin and skin structure infection (ABSSSI) in patients with diabetes mellitus","volume":"4","author":"Nowak","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2023.11.015_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108732","article-title":"Diabetes and acute bacterial skin and skin structure infections","volume":"174","author":"Falcone","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"issue":"Suppl","key":"10.1016\/j.jgar.2023.11.015_bib0035","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S1198-743X(16)30095-7","article-title":"Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections","author":"Russo","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2023.11.015_bib0036","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/1120009X.2017.1404277","article-title":"The role of dalbavancin in the multi-disciplinary management of wound infections in orthopaedic surgery","volume":"30","author":"Arena","year":"2018","journal-title":"J Chemother"},{"key":"10.1016\/j.jgar.2023.11.015_bib0037","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.idc.2020.10.007","article-title":"Skin and soft tissue infections in patients with diabetes mellitus","volume":"35","author":"Polk","year":"2021","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.jgar.2023.11.015_bib0038","first-page":"71","article-title":"Scottish Diabetes Foot Action Group. Diabetic foot infection: antibiotic therapy and good practice recommendations","author":"Barwell","year":"2017","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jgar.2023.11.015_bib0039","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1086\/656431","article-title":"Skin and soft-tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship","volume":"51","author":"Jenkins","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2023.11.015_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106918","article-title":"EN-DALBACEN 2.0 cohort: real-life study of dalbavancin as sequential\/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci","volume":"62","author":"Hidalgo-Tenorio","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2023.11.015_bib0041","doi-asserted-by":"crossref","first-page":"dlad044","DOI":"10.1093\/jacamr\/dlad044","article-title":"Cost analysis of dalbavancin versus standard of care for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in two Italian hospitals","volume":"5","author":"Bai","year":"2023","journal-title":"JAC Antimicrob Resist"},{"issue":"9","key":"10.1016\/j.jgar.2023.11.015_bib0042","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1080\/14787210.2021.1894130","article-title":"The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives","volume":"19","author":"Andreoni","year":"2021","journal-title":"Exp Rev Anti Infect Ther"},{"key":"10.1016\/j.jgar.2023.11.015_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvs.2019.08.244","article-title":"A systematic review of multidisciplinary teams to reduce major amputations for patients with diabetic foot ulcers","volume":"71","author":"Musuuza","year":"2020","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jgar.2023.11.015_bib0044","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40121-019-00275-4","article-title":"Dalbavancin reduces hospital stay and improves productivity for patients with acute bacterial skin and skin structure infections: the ENHANCE trial","volume":"9","author":"McCarthy","year":"2020","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jgar.2023.11.015_bib0045","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3390\/antibiotics10091129","article-title":"Use of dalbavancin in skin, bone and joint infections: a real-life experience in an Italian center","volume":"10","author":"Brescini","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2023.11.015_bib0046","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1080\/14740338.2021.1935864","article-title":"Systematic review and meta-analysis on the safety of dalbavancin","volume":"20","author":"Monteagudo-Martinez","year":"2021","journal-title":"Expert Opin Drug Safety"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716523002199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716523002199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:04:15Z","timestamp":1761991455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716523002199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":46,"alternative-id":["S2213716523002199"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2023.11.015","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dalbavancin real-life utilization among diabetic patients suffering from infections in Italy and Spain: The DALBADIA retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2023.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}